The Reactivity of Calicheamicin [Gamma]1I in the Minor Groove Of

Total Page:16

File Type:pdf, Size:1020Kb

The Reactivity of Calicheamicin [Gamma]1I in the Minor Groove Of DOI: 10.1002/chem.200700504 I The Reactivity of Calicheamicin g1 in the Minor Groove of DNA: The Decisive Role of the Environment Elfi Kraka,*[a] Tell Tuttle,[b] and Dieter Cremer[a] Abstract: Triggering and Bergman cyc- minor groove in such a way that out of man cyclization at body temperature I lization of calicheamicin g1 outside and a cyclohexenone by Michael addition only if present in its E chair form (acti- inside the minor groove of the an E rather than a Z form of a cyclo- vation enthalpy 16.4 kcalmolÀ1). An in- duplex 9mer-B-DNA sequence hexanone is formed, which in turn termediate biradical is formed (docking d(CACTCCTGG)·d(CCAGGAGTG) adopts a chair rather than a twistboat energy À13.6 kcalmolÀ1), which has a were investigated by using density form. Decisive for the stereochemistry sufficient lifetime to abstract two hy- functional theory and molecular me- of the Michael addition is the orienta- drogen atoms. Hydrogen abstraction is chanics (DFT and MM) descriptions in tion of the carbamate substituent at the a two- rather than one-step process which the ligand is completely de- headgroup of calicheamicin. Triggered and involves the C5(H5ACHTUNGRE ’) atom first scribed at the DFT and the receptor at calicheamicin can undergo the Berg- and then the T22(H4ACHTUNGRE ’) atom in line the MM level. The calculated docking with experimental observations. The energy of calicheamicin g I (À12.5 kcal decisive role of using a DFT rather 1 Keywords: ab initio calculations · molÀ1) is close to the measured value than an MM description for the ligand calicheamicin · DNA damage · of À9.7 kcalmolÀ1 and the site specifici- is documented. environmental effects · reaction ty is in line with experimental observa- mechanisms tions. Calicheamicin is triggered in the Introduction Enediyne 1 comprises the aglycone calicheamicinone (see also Scheme 2, Model 4) and the sugar tail with rings A, B, The discovery and recognition of the astonishingly selective C, D, and E. Discovered in 1986 as a fermentation-derived activity of the naturally occurring enediynes has generated antitumor antibiotic that is produced by Micromonospora intense chemical, biological, and medicinal interest in these echinospora (subspecies calichensis),[4] it possesses excellent remarkable compounds.[1–4] The naturally occurring ene- potency against murine tumors P388,[4] L1210 leukemias, diynes are a family of secondary metabolites that include and solid neoplasms such as colon 26 and B16 melanoma.[4,5] neocarzinostatin, esperamicin, dynemicin, kedarcidin, and The structure of 1 was determined in a stepwise approach I the target compound of this work, (À)-calicheamicin g1 (1, that included the X-ray diffraction analysis of rings B and C Scheme 1). as a single isolated unit,[6] extensive NMR studies of ring A and its attachment to ring B, ring D, and its connection to C,[5] as well as the isolated ring E.[7] The structure and at- [a] Prof. Dr. E. Kraka, Prof. Dr. D. Cremer tachment of the aglycone was established through a combi- Department of Chemistry and Department of Physics nation of NOE experiments and X-ray crystallography on University of the Pacific [6] 3601 Pacific Avenue, Stockton, CA 95211–0110 (USA) derivatives. The original stereochemistry, which was pro- Fax : (+1)194-62-607 posed for the aglycone at the position of the attachment to E-mail: [email protected] ring A, was later revised on the basis of the structure of es- [b] Dr. T. Tuttle peramicin. The revised stereochemistry places the glycosidic Department of Pure and Applied Chemistry linkage to ring A on the same side of the enediyne plane as University of Strathclyde the methyl trisulfide,[8] thus leading to S and R absolute con- 295 Cathedral Street Glasgow, G1 1XL (UK) figurations at the stereogenic centers C1 and C8. Supporting information for this article is available on the WWW The configuration of native 1 was later confirmed by the under http://www.chemeurj.org/ or from the author. enantioselective total synthesis of (À)- or (S,R)-calicheami- 9256 2007 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Chem. Eur. J. 2007, 13, 9256 – 9269 FULL PAPER Scheme 2. fraction analysis of the aglycone could be performed. The crystal structure is observed to have a relatively planar (slightly deformed to a twistchair) cyclohexenone ring and the carbamate group is oriented in such a way that it runs parallel to the enediyne warhead (i.e., opposite to the sulfur moiety). In its native form, 1 is inactive, only once it is triggered does it become active. The triggering involves a nucleophilic attack at the trisulfide linkage[3,4] leading to the thiol 2 (Scheme 1), which can undergo an intramolecular Michael addition to form the triggered calicheamicin 3, characterized by its tricyclic headgroup. Once triggered the molecule un- dergoes a Bergman cyclization[13,14] via TS(3–4)ACHTUNGRE to form the singlet biradical 4-S, which, if properly positioned in the minor groove, subsequently abstracts two hydrogen atoms from the DNA strands to form the stable benzene derivative Scheme 1. 5. Alternatively, 4-S can undergo a retro-Bergman reaction via TS(4–6)ACHTUNGRE yielding the open enediyne 6 (Scheme 1). Hydrogen abstraction by 4-S leads to oxidative double- cone[9] and (À)- or (S,R)-1 in their enantiomerically pure strand scission, which causes irreversible damage and cell form.[10] Syntheses of (À)-calicheamicinone through differ- death (apoptosis).[1–4,15,16] This was first demonstrated by ent synthetic routes have also been successfully undertak- Zein and co-workers[17] through the ability of 1 to cause in en,[11, 12] and in the course of the synthetic work an X-ray dif- vitro double-strand scission when in the presence of thiols. Chem. Eur. J. 2007, 13, 9256 – 9269 2007 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.chemeurj.org 9257 E. Kraka et al. Furthermore, the sequence specificity of the cut site of 1 ation) to (from) DNA. This, however, exceeds the possibili- was found to be well defined.[17] Chemical footprinting stud- ties of modern QM/MM molecular dynamics (MD) simula- ies established the binding site for calicheamicin as oligopur- tions. Alternatively, one could attempt to describe the ine·oligopyrimidine tetranucleotide stretches, with the high- ligand and receptor exclusively by MM. This implies setting est specificity being identified as the (T-C-C-T)·(A-G-G-A)ACHTUNGRE up a suitable force field that is able to describe the enediyne sequence.[17–19] It was also demonstrated that 1 abstracts hy- unit and the chemical processes of this unit along the Berg- drogen atoms from DNA rather than from the surrounding man cyclization path while bound to DNA. Such a force medium (proteins, etc.) and that the carbon sites that extract field, however, is hampered by the principal problem of de- the DNA hydrogens are exactly the proradical carbons in- scribing quantitatively quantum-mechanical processes with volved in the Bergman cyclization.[20] empirical force fields. Because these basic questions have There have been numerous studies clarifying the site spe- not been solved and will not be solved in the near future cificity of hydrogen abstraction,[21–23] its dependence on the one has to revert to a simplified solution. In this work we oligosaccharide tail,[16,24–27] the interactions of the tail with extensively used DFT to describe ligand 1 as accurately as DNA, and their mutual repositioning.[28, 29] These studies possible. Once the configuration of the ligand 1 was deter- were extensively based on NMR measurements, which in mined it was kept during the docking to the receptor DNA. turn laid the basis for molecular modeling descriptions.[30, 31] The latter was described at the MM level and the docking So far, only a fewquantum chemical studies have been car- process was described with the help of empirical scoring ried out to investigate the triggering of the aglycone (model functions that were parameterized to get useful complex 4 in Scheme 2),[32] the stereochemistry of its Michael addi- free binding energies in the case of proteins. In this way, we tion,[33] or the Bergman cyclization of the headgroup.[34] A obtained a rigid docking description of a QM+ MM (rather full quantum chemical investigation of 1 or 3 utilizing either than a QM/MM) description, the usefulness of which was density functional theory (DFT) or wave function theory described in previous work.[42] has so far not been carried out. Based on previous work[40–43] and according to the argu- In this work, we present a DFT and molecular mechanics ments given in the Supporting Information, we used DFT (MM) investigation in which the ligand (1, 3 or their follow- with Poples 6–31G(d)[44] and 3–21G split-valence basis up products) is for the first time completely described at the sets[45] in connection with the hybrid functional B3LYP[46–48] DFT level and the receptor by MM. We investigate the en- to describe 1. (For calculations with larger basis sets such as ergetics and stereochemistry of the triggering and the Berg- 6–31G(d,p),ACHTUNGRE 6–31+G(d), 6–311G(d,p),ACHTUNGRE and 6–311 ++G- man reaction in dependence of the substituents sitting at the (3df,3pd)ACHTUNGRE and the use of CCSD(T), see Supporting Informa- headgroup. For the latter purpose, we stepwise simplify the tion.) At B3LYP/3–21G, the geometries of 1, 3 and all triggered molecule 3 to obtain the models 1 to 7 shown in follow-up products were fully optimized. Restricted DFT Scheme 2. Normally, it is assumed that the headgroup deter- (RDFT) calculations were carried out for the singlet states, mines the energetics of the Bergman reaction.
Recommended publications
  • C-1027, a Radiomimetic Enediyne Anticancer Drug, Preferentially Targets Hypoxic Cells
    Research Article C-1027, A Radiomimetic Enediyne Anticancer Drug, Preferentially Targets Hypoxic Cells Terry A. Beerman,1 Loretta S. Gawron,1 Seulkih Shin,1 Ben Shen,2 and Mary M. McHugh1 1Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York;and 2Division of Pharmaceutical Sciences, University of Wisconsin National Cooperative Drug Discovery Group, and Department of Chemistry, University of Wisconsin, Madison, Wisconsin Abstract identified primarily from studies with neocarzinostatin (NCS), a The hypoxic nature of cells within solid tumors limits the holo-form drug, consisting of an apoprotein carrier and an active efficacy of anticancer therapies such as ionizing radiation and chromophore, and was assumed to be representative of all agents conventional radiomimetics because their mechanisms re- in this class (11). The NCS chromophore contains a bicyclic quire oxygen to induce lethal DNA breaks. For example, the enediyne that damages DNA via a Myers-Saito cycloaromatization conventional radiomimetic enediyne neocarzinostatin is 4- reaction, resulting in a 2,6-indacene diradical structure capable of fold less cytotoxic to cells maintained in low oxygen (hypoxic) hydrogen abstractions from deoxyribose (12, 13). Subsequent to compared with normoxic conditions. By contrast, the ene- generation of a sugar radical, reaction with oxygen quickly and diyne C-1027 was nearly 3-fold more cytotoxic to hypoxic than efficiently leads to formation of hydroxyl radicals that induce to normoxic cells. Like other radiomimetics, C-1027 induced DSBs/SSBs at a 1:5 ratio. The more recently discovered holo-form DNA breaks to a lesser extent in cell-free, or cellular hypoxic, enediyne C-1027 (Fig.
    [Show full text]
  • Enediynes, Enyneallenes, Their Reactions, and Beyond
    Advanced Review Enediynes, enyne-allenes, their reactions, and beyond Elfi Kraka∗ and Dieter Cremer Enediynes undergo a Bergman cyclization reaction to form the labile 1,4-didehy- drobenzene (p-benzyne) biradical. The energetics of this reaction and the related Schreiner–Pascal reaction as well as that of the Myers–Saito and Schmittel reac- tions of enyne-allenes are discussed on the basis of a variety of quantum chemical and available experimental results. The computational investigation of enediynes has been beneficial for both experimentalists and theoreticians because it has led to new synthetic challenges and new computational methodologies. The accurate description of biradicals has been one of the results of this mutual fertilization. Other results have been the computer-assisted drug design of new antitumor antibiotics based on the biological activity of natural enediynes, the investigation of hetero- and metallo-enediynes, the use of enediynes in chemical synthesis and C materials science, or an understanding of catalyzed enediyne reactions. " 2013 John Wiley & Sons, Ltd. How to cite this article: WIREs Comput Mol Sci 2013. doi: 10.1002/wcms.1174 INTRODUCTION symmetry-allowed pericyclic reactions, (ii) aromatic- ity as a driving force for chemical reactions, and (iii) review on the enediynes is necessarily an ac- the investigation of labile intermediates with biradical count of intense and successful interdisciplinary A character. The henceforth called Bergman cyclization interactions of very different fields in chemistry provided deeper insight into the electronic structure involving among others organic chemistry, matrix of biradical intermediates, the mechanism of organic isolation spectroscopy, quantum chemistry, biochem- reactions, and orbital symmetry rules.
    [Show full text]
  • Inotuzumab Ozogamicin Is an Investigational Agent and Has Not Been Approved for Marketing by Any Regulatory Agency at This Time
    Inotuzumab Ozogamicin is an investigational agent and has not been approved for marketing by any regulatory agency at this time. ABOUT INOTUZUMAB OZOGAMICIN Inotuzumab ozogamicin is an investigational antibody-drug conjugate (ADC) comprised of a monoclonal antibody (mAb) targeting CD22, a cell surface antigen found on cancer cells in almost all B-ALL patients, linked to a cytotoxic agent.1,2 When inotuzumab ozogamicin binds to the CD22 antigen on B-cells, it is internalized into the cell, where the cytotoxic agent calicheamicin is released to destroy the cell.3 ABOUT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) Acute lymphoblastic leukemia (ALL) in adults is an aggressive leukemia that can be fatal within a matter of months if left untreated.4 While many potential treatments have been studied, only a limited number of medicines for relapsed or refractory adults with ALL have been approved by the FDA and other regulatory authorities in the past decade. The current standard treatment is intensive, lengthy chemotherapy with the goal of halting the signs and symptoms of ALL (called hematologic remission) and patients becoming eligible for a stem cell transplant.4 UNMET NEEDS IN ADULT ALL Statistics & Patient Characteristics Statistics & Patient Characteristics • In 2017, it is estimated that 5,970 cases of ALL • Approximately half of U.S. adults who learn they will be diagnosed in the United States, with about have ALL this year will not respond to commonly 4 in 10 cases occurring in adults.5 used chemotherapy agents (e.g., be refractory) or will eventually see their disease return (e.g., relapse).5 • While significant strides have been made in treating children with ALL, the opposite is true for adults with • The outlook for adults with relapsed or refractory the disease.
    [Show full text]
  • WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT (51) International Patent Classification: achusetts 021 15 (US). THE BROAD INSTITUTE, A61K 51/10 (2006.01) G01N 33/574 (2006.01) INC. [US/US]; 415 Main Street, Cambridge, Massachu C07K 14/705 (2006.01) A61K 47/68 (2017.01) setts 02142 (US). MASSACHUSETTS INSTITUTE OF G01N 33/53 (2006.01) TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). (21) International Application Number: PCT/US2017/055625 (72) Inventors; and (71) Applicants: KUCHROO, Vijay K. [IN/US]; 30 Fairhaven (22) International Filing Date: Road, Newton, Massachusetts 02149 (US). ANDERSON, 06 October 2017 (06.10.2017) Ana Carrizosa [US/US]; 110 Cypress Street, Brookline, (25) Filing Language: English Massachusetts 02445 (US). MADI, Asaf [US/US]; c/o The Brigham and Women's Hospital, Inc., 75 Francis (26) Publication Language: English Street, Boston, Massachusetts 021 15 (US). CHIHARA, (30) Priority Data: Norio [US/US]; c/o The Brigham and Women's Hospital, 62/405,835 07 October 2016 (07.10.2016) US Inc., 75 Francis Street, Boston, Massachusetts 021 15 (US). REGEV, Aviv [US/US]; 15a Ellsworth Ave, Cambridge, (71) Applicants: THE BRIGHAM AND WOMEN'S HOSPI¬ Massachusetts 02139 (US). SINGER, Meromit [US/US]; TAL, INC. [US/US]; 75 Francis Street, Boston, Mass c/o The Broad Institute, Inc., 415 Main Street, Cambridge, (54) Title: MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS CD4 FIG.
    [Show full text]
  • Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
    CCR FOCUS Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin Alejandro D. Ricart Abstract Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently sensitive to cytotoxic agents. CD33 and CD22 are specific markers of myeloid leukemias and B-cell malignancies, respectively. These endocytic receptors are ideal for an ADC strategy because they can effectively carry the cytotoxic payload into the cell. Gemtuzumab ozogamicin (GO, Mylotarg) and inotuzumab ozogamicin consist of a derivative of calichea- micin (a potent DNA-binding cytotoxic antibiotic) linked to a humanized monoclonal IgG4 antibody directed against CD33 or CD22, respectively. Both of these ADCs have a target-mediated pharmacokinetic disposition. GO was the first drug to prove the ADC concept in the clinic, specifically in phase II studies that included substantial proportions of older patients with relapsed acute myeloid leukemia. In contrast, in phase III studies, it has thus far failed to show clinical benefit in first-line treatment in combination with standard chemotherapy. Inotuzumab ozogamicin has shown remarkable clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma, and it has started phase III evaluation. The safety profile of these ADCs includes reversible myelosuppression (especially neutropenia and thrombocyto- penia), elevated hepatic transaminases, and hyperbilirubinemia. There have been postmarketing reports of hepatotoxicity, especially veno-occlusive disease, associated with GO. The incidence is 2%, but patients who undergo hematopoietic stem cell transplantation have an increased risk. As we steadily move toward the goal of personalized medicine, these kinds of agents will provide a unique opportunity to treat selected patient subpopulations based on the expression of their specific tumor targets.
    [Show full text]
  • Molecular Biosystems
    Molecular BioSystems View Article Online PAPER View Journal | View Issue Cloning and sequencing of the kedarcidin biosynthetic Cite this: Mol. BioSyst., 2013, gene cluster from Streptoalloteichus sp. ATCC 53650 9, 478 revealing new insights into biosynthesis of the enediyne family of antitumor antibiotics† Jeremy R. Lohman,a Sheng-Xiong Huang,a Geoffrey P. Horsman,b Paul E. Dilfer,a Tingting Huang,a Yihua Chen,b Evelyn Wendt-Pienkowskib and Ben Shenz*abcd Enediyne natural product biosynthesis is characterized by a convergence of multiple pathways, generating unique peripheral moieties that are appended onto the distinctive enediyne core. Kedarcidin (KED) possesses two unique peripheral moieties, a (R)-2-aza-3-chloro-b-tyrosine and an iso- propoxy-bearing 2-naphthonate moiety, as well as two deoxysugars. The appendage pattern of these peripheral moieties to the enediyne core in KED differs from the other enediynes studied to date with respect to stereochemical configuration. To investigate the biosynthesis of these moieties and expand our understanding of enediyne core formation, the biosynthetic gene cluster for KED was cloned from Streptoalloteichus sp. ATCC 53650 and sequenced. Bioinformatics analysis of the ked cluster revealed the presence of the conserved genes encoding for enediyne core biosynthesis, type I and type II polyketide synthase loci likely responsible for 2-aza-L-tyrosine and 3,6,8-trihydroxy-2-naphthonate Received 16th November 2012, formation, and enzymes known for deoxysugar biosynthesis. Genes homologous to those responsible Accepted 20th January 2013 for the biosynthesis, activation, and coupling of the L-tyrosine-derived moieties from C-1027 and DOI: 10.1039/c3mb25523a maduropeptin and of the naphthonate moiety from neocarzinostatin are present in the ked cluster, supporting 2-aza-L-tyrosine and 3,6,8-trihydroxy-2-naphthoic acid as precursors, respectively, for the www.rsc.org/molecularbiosystems (R)-2-aza-3-chloro-b-tyrosine and the 2-naphthonate moieties in KED biosynthesis.
    [Show full text]
  • Probing Interaction Motifs for Ligand Binding Prediction from Three
    PROBING INTERACTION MOTIFS FOR LIGAND BINDING PREDICTION FROM THREE PERSPECTIVES: ASSESSING PROTEIN SIMILARITY, LIGAND SIMILARITY AND COMPONENTS OF PROTEIN-LIGAND INTERACTIONS By Nan Liu A DISSERTATION Submitted to Michigan State University in partial fulfillment of the requirements for the degree of Chemistry – Doctor of Philosophy 2015 ABSTRACT PROBING INTERACTION MOTIFS FOR LIGAND BINDING PREDICTION FROM THREE PERSPECTIVES: ASSESSING PROTEIN SIMILARITY, LIGAND SIMILARITY AND COMPONENTS OF PROTEIN-LIGAND INTERACTIONS By Nan Liu The interactions between small molecules and diverse enzyme, membrane receptor and channel proteins are associated with important biological processes and diseases. This makes the study of binding motifs between proteins and ligands appealing to scientists. We use multiple computational techniques to unveil the protein-ligand interaction motifs from three perspectives. Firstly, from the perspective of proteins, by comparing the structure differences and common features of different binding sites for the same ligand, 3-dimensional motifs that represent the favorable interactions of the same ligands can be extracted. The goal is for such a motif to represent the shared features for binding a certain ligand in unrelated proteins, while discriminating from other ligands. The 3-dimensional motifs for cholesterol and cholate binding to non-homologous protein sites have been extracted, using SimSite3D alignment and analysis of the conserved interactions between these sites. The 3-dimensional protein motif for cholesterol binding can give about 80% accuracy of true positive sites with a low false positive rate. Furthermore, an online server CholMine was established so that the users can use this approach to predict cholesterol and cholate binding sites in proteins of interest.
    [Show full text]
  • The Novel Calicheamicin-Conjugated CD22 Antibody Inotuzumab Ozogamicin (CMC-544) Effectively Kills Primary Pediatric Acute Lymphoblastic Leukemia Cells
    Leukemia (2012) 26, 255–264 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu ORIGINAL ARTICLE The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells JF de Vries1, CM Zwaan2, M De Bie1, JSA Voerman1, ML den Boer2, JJM van Dongen1 and VHJ van der Velden1 1Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands and 2Department of Pediatric Oncology/Hematology, Erasmus MC, Sophia Children’s Hospital, Rotterdam, The Netherlands We investigated whether the newly developed antibody (Ab) - One of these new approaches is antibody (Ab)-targeted targeted therapy inotuzumab ozogamicin (CMC-544), consisting chemotherapy, where the Ab-part of the compound is used to of a humanized CD22 Ab linked to calicheamicin, is effective in specifically deliver the cytostatic drug to the target cell, resulting pediatric primary B-cell precursor acute lymphoblastic leuke- mia (BCP-ALL) cells in vitro, and analyzed which parameters in less or no bystander cell death. One of the first examples of Ab- determine its efficacy. CMC-544 induced dose-dependent cell based delivery is gemtuzumab ozogamicin (GO, Mylotarg kill in the majority of BCP-ALL cells, although IC50 values varied or CMA-676), which consists of a humanized CD33 Ab substantially (median 4.8 ng/ml, range 0.1–1000 ng/ml at 48 h). covalently linked to a derivative of the potent DNA-damaging The efficacy of CMC-544 was highly dependent on calicheami- cytotoxic agent calicheamicin.7,8 Calicheamicin induces cell cin sensitivity and CD22/CMC-544 internalization capacity of BCP-ALL cells, but hardly on basal and renewed CD22 death in its target cells by interaction with double-helical DNA in expression.
    [Show full text]
  • Selective Proteolytic Activity of the Antitumor Agent Kedarcidin N
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 8009-8012, September 1993 Biochemistry Selective proteolytic activity of the antitumor agent kedarcidin N. ZEIN*t, A. M. CASAZZA*, T. W. DOYLE*, J. E. LEETt, D. R. SCHROEDERt, W. SOLOMON*, AND S. G. NADLER§ *Cancer Drug Discovery, Molecular Drug Mechanism, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 4000, Princeton, NJ 08543-4000; tChemistry Division, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5100, Wallingford, CT 06492-7660; and §Antitumor Immunology, Bristol-Myers Squibb Pharmaceutical Research Institute, 3005 1st Avenue, Seattle, WA 98121 Communicated by William P. Jencks, May 27, 1993 ABSTRACT Kedarcidin is a potent antitumor antibiotic there is substantial in vitro chemical and structural informa- chromoprotein, composed of an enediyne-containing chro- tion (4-21). Furthermore, it was proposed that the neocarzi- mophore embedded in a highly acidic single chain polypeptide. nostatin apoprotein stabilizes and regulates the availability of The chromophore was shown to cleave duplex DNA site- the labile chromophore (4-9). As previously shown for specifically in a single-stranded manner. Herein, we report that neocarzinostatin (4-9), DNA experiments with the isolated in vitro, the kedarcidin apoprotein, which lacks any detectable chromophore and the kedarcidin chromoprotein demon- chromophore, cleaves proteins selectively. Histones that are the strated that DNA cleavage was mostly due to the chro- most opposite in net charge to the apoprotein are cleaved most mophore (N.Z. and W.S., unpublished data). However, readily. Our findings imply that the potency of kedarcidin cytotoxicity assays using human colon cancer cell lines HCT results from the combination of a DNA damaging-chro- 116 showed the chromophore and the chromoprotein to mophore and a protease-like apoprotein.
    [Show full text]
  • Total Synthesis of Calicheamicin Type Enediyne Natural Products
    Total Synthesis of Calicheamicin Type Enediyne Natural Products 17/09/02 Yuki Fujimoto 1 Contents 2 Enediyne Natural Products SSS Me O OMe NHCO 2Me MeO O O H OH HO O N O O O OMe S O OH HO I OH O OMe O NHEt I calicheamicin 1 (calicheamicin type) OMe O O O O CO 2H OH O HN O O OMe OH O O MeH N HO OH O OH O OH dynemicin A (dynemicin type) neocarzinostatin chromophore (chromoprotein type) 3 Bergman Cyclization Jones, R. R.; Bergman, R. G . J. Am. Chem. Soc. 1972 , 94 , 660. 4 Distance of Diyne a) Nicolaou, K. C.; Zuccarello, G.; Ogawa, Y.; Schweiger, E. J.; Kumazawa, T. J. Am. Chem. Soc. 1988 , 110 , 4866. 5 b) Nicolaou, K. C.; Dai, W. M. Angew. Chem. Int. Ed. Engl. 1991 , 30 , 1387. Calicheamicin Type Action Mechanism Nicolaou, K. C.; Dai, W. M. Angew. Chem. Int. Ed. Engl. 1991 , 30 , 1387 6 Contents 7 Introduction of Calicheamicin SSS Me O OMe NHCO 2Me MeO O O H OH HO O N O O O OMe S O OH HO I OH O OMe NHEt I O calicheamicin 1 SSS Me Isolation O 1) NHCO 2Me bacterial strain Micromonospora echinospora ssp calichensis I Total synthesis of calicheamicin 1 HO OH Nicolaou, K. C. (1992, enantiomeric) 2) Danishefsky (1994, enantiomeric) 3) Total synthesis of calicheamicinone Danishefsky, S. J. (1990, racemic) 4) Nicolaou, K. C. (1993, enantiomeric) 5) calicheamicinone Clive, D. L. J. (1996, racemic) 6) (calicheamicin aglycon) Magnus, P. (1998, racemic) 7) 1) Borders, D.
    [Show full text]
  • Precursor-Directed Biosynthesis of Azinomycin a and Related Metabolites by Streptomyces Sahachi- Roi
    ORBIT-OnlineRepository ofBirkbeckInstitutionalTheses Enabling Open Access to Birkbeck’s Research Degree output Precursor-Directed Biosynthesis of Azinomycin A and Related Metabolites by Streptomyces sahachi- roi https://eprints.bbk.ac.uk/id/eprint/40052/ Version: Full Version Citation: Sebbar, Abdel-Ilah (2014) Precursor-Directed Biosynthesis of Azinomycin A and Related Metabolites by Streptomyces sahachiroi. [Thesis] (Unpublished) c 2020 The Author(s) All material available through ORBIT is protected by intellectual property law, including copy- right law. Any use made of the contents should comply with the relevant law. Deposit Guide Contact: email Precursor-Directed Biosynthesis of Azinomycin A and Related Metabolites by Streptomyces sahachiroi Abdel-Ilah Sebbar Department of Biological Sciences School of Science Birkbeck College University of London A thesis submitted to the University of London for the degree of Doctor of Philosophy August 2014 Declaration The work presented in this thesis in entirely on my own, except where I have either acknowledged help from a known person or given a published reference. 15/8/14 Signed: ………………. Date:… ………………... PhD student: Abdel-Ilah Sebbar Department of Biological Sciences School of Science Birkbeck College University of London 15/8/14 Signed: Date: …………………... Supervisor: Dr. Philip Lowden Department of Biological Sciences School of Science Birkbeck College University of London 2 Abstract Azinomycins A and B are bioactive compounds produced by Streptomyces species. These naturally occurring antibiotics exhibit potent in vitro cytotoxic activity, promising in vivo antitumor activity and exert their effect by disruption of DNA replication by the formation of interstrand cross-links. The electrophilic C-10 and C-21 carbons contained within the aziridine and epoxide moieties are known to be responsible for the interstrand cross-links through alkylation of N-7 atoms of guanine bases.
    [Show full text]
  • Induction of Apoptosis by Enediyne Antibiotic Calicheamicin 0II
    Oncogene (2003) 22, 9107–9120 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc ORIGINAL PAPERS Induction of apoptosis by enediyne antibiotic calicheamicin 0II proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner Aram Prokop1,4, Wolf Wrasidlo2,4, Holger Lode2, Ralf Herold1, Florian Lang3,5,Gu¨ nter Henze1, Bernd Do¨ rken3, Thomas Wieder3,5,6 and Peter T Daniel*,3,6 1Department of Pediatric Oncology/Hematology, University Medical Center Charite´, Humboldt University of Berlin, Berlin 13353, Germany; 2Department of General Pediatrics, University Medical Center Charite´, Humboldt University of Berlin, Berlin 13353, Germany; 3Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite´, Humboldt University of Berlin, Berlin 13125, Germany Calicheamicin 0II is a member of the enediyne class of Keywords: calicheamicin; apoptosis; caspase-3; Bax; antitumor antibiotics that bind to DNA and induce Bcl-2; cytochrome c; mitochondria; BJAB; Jurkat; apoptosis. These compounds differ, however, from con- HCT116 ventional anticancer drugs as they bind in a sequence- specific manner noncovalently to DNA and cause sequence-selective oxidation of deoxyriboses and bending of the DNA helix. Calicheamicin is clinically employed as Introduction immunoconjugate to antibodies directed against, for example, CD33 in the case of gemtuzumab ozogamicin. In contrast to necrosis, apoptosis is a morphologically Here, we show by the use of the unconjugated drug that and biochemically defined form of cell death that plays a calicheamicin-induced apoptosis is independent from role under different physiological conditions, such as death-receptor/FADD-mediated signals. Moreover, cali- cell turnover, the immune response or embryonic cheamicin triggers apoptosis in a p53-independent manner development.
    [Show full text]